Cargando…

Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review

BACKGROUND: Macular oedema secondary to retinal vein occlusion (RVO) can cause vision loss due to blockage of the central retinal vein (CRVO) or a branch retinal vein (BRVO). This systematic review assessed the efficacies of widely used treatments for macular oedema secondary to RVO and the feasibil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glanville, Julie, Patterson, Jacoby, McCool, Rachael, Ferreira, Alberto, Gairy, Kerry, Pearce, Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904417/ https://www.ncbi.nlm.nih.gov/pubmed/24447389 http://dx.doi.org/10.1186/1471-2415-14-7

Ejemplares similares

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Perifoveal Microcirculation in Macular Oedema with Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2012)

Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis
por: Ford, John A, et al.
Publicado: (2014)

Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
por: Hikichi, Taiichi, et al.
Publicado: (2014)

Treatments for macular oedema following central retinal vein occlusion: systematic review
por: Ford, John A, et al.
Publicado: (2014)

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion
por: Ang, Juan Lyn, et al.
Publicado: (2020)

Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
por: Hunter, Alexandra, et al.
Publicado: (2022)

Clinical characteristics of branch retinal vein occlusion with increased retinal haemorrhage during treatment for macular oedema
por: Lee, You Hyun, et al.
Publicado: (2020)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Rodríguez-Fernández, Carmen Antía, et al.
Publicado: (2022)

Antivascular endothelial growth factor for macular oedema secondary to retinal vein occlusion: a systematic review and meta-analysis
por: Xu, Shanshan, et al.
Publicado: (2022)

Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
por: Gildea, David, et al.
Publicado: (2023)

Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis
por: Regnier, Stephane A, et al.
Publicado: (2015)

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
por: Bhandari, Sanjeeb, et al.
Publicado: (2022)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion – an 18-month prospective cohort study
por: O’Day, Roderick, et al.
Publicado: (2020)

Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety
por: Mishra, S. K., et al.
Publicado: (2018)

Short-term and long-term results after intravitreal bevacizumab therapy for macular oedema in branch retinal vein occlusion
por: Pidro, Ajla, et al.
Publicado: (2022)

Comparative Evaluation Between Ranibizumab Combined with Laser and Bevacizumab Combined with Laser Versus Laser Alone for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Azad, Shorya Vardhan, et al.
Publicado: (2014)

Prevalence of Serous Macular Detachment in Recurrent Macular Edema Secondary to Retinal Vein Occlusion
por: Şekeroğlu, Mehmet Ali, et al.
Publicado: (2022)

Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion
por: Udaondo, Patricia, et al.
Publicado: (2011)

Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
por: Gale, Richard, et al.
Publicado: (2021)

Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
por: Horner, Faye, et al.
Publicado: (2020)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion
por: Modi, Yasha S., et al.
Publicado: (2023)

Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion
por: Azad, Rajvardhan, et al.
Publicado: (2012)

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Gutiérrez, Juan Carlos Mesa, et al.
Publicado: (2008)

Evaluation of non-exudative microcystoid macular abnormalities secondary to retinal vein occlusion
por: Francone, Anibal, et al.
Publicado: (2021)

Factors correlated with the resolution of macular oedema after one dose injection of intravitreal triamcinolone acetonide treatment in branch retinal vein occlusion
por: Zhang, Shuang, et al.
Publicado: (2016)

Dexamethasone intravitreous implant vs bevacizumab for central retinal vein occlusion‐related macular oedema: A prospective randomized comparison—Comment
por: Wen, Dejia, et al.
Publicado: (2019)

The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy
por: Nicholson, Luke, et al.
Publicado: (2021)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Increased intraocular inflammation in retinal vein occlusion is independent of circulating immune mediators and is involved in retinal oedema
por: Zhou, Yufan, et al.
Publicado: (2023)

Aflibercept in macular edema secondary to retinal vein occlusion: A real life study
por: Ozkaya, Abdullah, et al.
Publicado: (2017)

EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION
por: Sun, Zuhua, et al.
Publicado: (2017)

Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion
por: Spooner, Kimberly, et al.
Publicado: (2020)

Management of macular edema with branch retinal vein occlusion in a case of secondary polycythemia
por: Singh, Sumeer, et al.
Publicado: (2019)

Intravitreal injection of conbercept combined with retinal photocoagulation on macular edema secondary to branch retinal vein occlusion
por: Wang, Bing, et al.
Publicado: (2020)

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial
por: Mitchell, Paul, et al.
Publicado: (2012)

Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result
por: Lip, P L, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v0cdgnjjoeu96h2coj9vrujemo